Cargando…

Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer

De novo metastatic or recurrence of prostate cancer (PC) remains life-threatening. Circulating tumor cells (CTCs) are noninvasive biomarkers and provide unique information that could enable tailored treatment. This study evaluated the impact of CTCs in PC patients eligible for peptide vaccine therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guldvik, Ingrid Jenny, Ekseth, Lina, Kishan, Amar U., Stensvold, Andreas, Inderberg, Else Marit, Lilleby, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303369/ https://www.ncbi.nlm.nih.gov/pubmed/34206815 http://dx.doi.org/10.3390/jpm11070605

Ejemplares similares

Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy
por: Ma, Ting Martin, et al.
Publicado: (2020)

Long-term surviving cancer patients as a source of therapeutic TCR
por: Inderberg, Else Marit, et al.
Publicado: (2020)

Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
por: Guldvik, Ingrid Jenny, et al.
Publicado: (2022)

Sympathetic improvement of cancer vaccine efficacy
por: Inderberg, Else Marit, et al.
Publicado: (2020)

Use of bisphosphonates in advanced prostate cancer: Current status
por: Lilleby, Wolfgang
Publicado: (2007)

Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
por: Lilleby, Wolfgang, et al.
Publicado: (2015)

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

Emerging Biomarkers for Immunotherapy in Glioblastoma
por: Mensali, Nadia, et al.
Publicado: (2022)

Pelvic nodal radiotherapy in Gleason grade group 5 prostate cancer
por: Cook, Kiri, et al.
Publicado: (2020)

Local failure in high grade prostate cancer: the importance of local and systemic therapy
por: Kishan, Amar U., et al.
Publicado: (2020)

A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome
por: Ryg, Una, et al.
Publicado: (2022)

Image-guided radiotherapy for prostate cancer
por: Dang, Audrey, et al.
Publicado: (2018)

Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
por: Guldvik, Ingrid J., et al.
Publicado: (2020)

Acute toxicities after extremely hypofractionated radiotherapy for prostate cancer: lessons from HYPO-RT-PC and PACE-B
por: Juarez, Jesus E., et al.
Publicado: (2020)

MR-Guided Radiotherapy for Prostate Cancer
por: Tocco, Boris R., et al.
Publicado: (2020)

Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
por: Inderberg-Suso, Else-Marit, et al.
Publicado: (2012)

The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology
por: Nakken, Sigve, et al.
Publicado: (2021)

T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
por: Inderberg, Else M., et al.
Publicado: (2017)

Determination of CAR T cell metabolism in an optimized protocol
por: Joaquina, Sandy, et al.
Publicado: (2023)

Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
por: Aljabri, Belal, et al.
Publicado: (2021)

MRI-guided Dose-escalated Salvage Radiotherapy for Bulky Bladder Neck Recurrence of Prostate Cancer
por: Kishan, Amar U, et al.
Publicado: (2018)

Risk of Tumor Upstaging With Prostate-Specific Membrane Antigen Positron Emission Tomography in Patients With High-Risk Prostate Cancer
por: Brant, Aaron, et al.
Publicado: (2022)

Editorial: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options
por: Zaorsky, Nicholas G., et al.
Publicado: (2020)

Magnetic Resonance Imaging Guidance Mitigates the Effects of Intrafraction Prostate Motion During Stereotactic Body Radiotherapy for Prostate Cancer
por: Hegde, John V, et al.
Publicado: (2018)

NK cells specifically TCR-dressed to kill cancer cells
por: Mensali, Nadia, et al.
Publicado: (2019)

MRI-Guided Radiation Therapy for Prostate Cancer: The Next Frontier in Ultrahypofractionation
por: Benitez, Cecil M., et al.
Publicado: (2023)

Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
por: Lilleby, Oscar, et al.
Publicado: (2019)

Stereotactic body radiation therapy use for high risk prostate cancer in the United States
por: Patel, Sagar A., et al.
Publicado: (2020)

Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

A personalized decision aid for prostate cancer shared decision making
por: Bagshaw, Hilary P., et al.
Publicado: (2021)

Chimeric antigen receptor preparation from hybridoma to T-cell expression
por: Köksal, Hakan, et al.
Publicado: (2019)

P611: CD37 AS A MOLECULAR TARGET FOR CAR-T CELLS AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA
por: Kusowska, Aleksandra, et al.
Publicado: (2023)

Prognostic Role of Dynamic Changes in Serological Markers in Metastatic Hormone Naïve Prostate Cancer
por: Roy, Soumyajit, et al.
Publicado: (2023)

Impact of Health-related Quality of Life and Prediagnosis Risk of Major Depressive Disorder on Treatment Choice in Low- and Intermediate-Risk Prostate Cancer
por: Riskin-Jones, Hannah, et al.
Publicado: (2020)

Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer
por: Ramberg, Håkon, et al.
Publicado: (2021)

Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison
por: Wu, Trudy C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ece3il33o9lpcoblu6oige78ci